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Long‑term treated HIV infection 
is associated with platelet 
mitochondrial dysfunction
Wouter A. van der Heijden1*, Lisa van de Wijer1, Martin Jaeger1, Karin Grintjes1, 
Mihai G. Netea1,2, Rolf T. Urbanus3, Reinout van Crevel1, Lambertus P. van den Heuvel4,5, 
Maaike Brink5, Richard J. Rodenburg4, Philip G. de Groot1,6, Andre J. van der Ven1 & 
Quirijn de Mast1 
HIV infection and antiretroviral therapy have been linked to mitochondrial dysfunction. The role 
of platelet mitochondrial dysfunction in thrombosis, immunoregulation and age‑related diseases 
is increasingly appreciated. Here, we studied platelet mitochondrial DNA content  (mtDNApl) and 
mitochondrial function in people living with HIV (PLHIV) and related this to platelet function. In a 
cohort of 208 treated PLHIV and 56 uninfected controls,  mtDNApl was quantified, as well as platelet 
activation, platelet agonist‑induced reactivity and inflammation by circulating factors and flow 
cytometry. In a subgroup of participants, the metabolic activity of platelets was further studied by 
mitochondrial function tests and the Seahorse Flux Analyzer. PLHIV had significantly lower  mtDNApl 
compared to controls (8.5 copies/platelet (IQR: 7.0–10.7) vs. 12.2 copies/platelet (IQR: 9.5–16.6); 
p < 0.001), also after correction for age, sex and BMI. Prior zidovudine‑use (n = 46) was associated 
with a trend for lower  mtDNApl. PLHIV also had reduced ex vivo platelet reactivity and mean platelet 
volume compared to controls.  MtDNApl correlated positively with both platelet parameters and 
correlated negatively with inflammatory marker sCD163. Mitochondrial function tests in a subgroup 
of participants confirmed the presence of platelet mitochondrial respiration defects. Platelet 
mitochondrial function is disturbed in PLHIV, which may contribute to platelet dysfunction and 
subsequent complications. Interventions targeting the preservation of normal platelet mitochondrial 
function may ultimately prove beneficial for PLHIV.
Mitochondrial dysfunction is a well-known phenomenon in people living with HIV (PLHIV), which has been 
linked with the use of nucleoside reverse transcriptase inhibitors (NRTIs)1–5. The main mechanism underlying 
NRTI toxicity is inhibition of mitochondrial DNA polymerase γ and increased oxidative stress, resulting in mito-
chondrial DNA (mtDNA)  depletion6–8, and mitochondrial dysfunction at the tissue  level7,9. These adverse effects 
were greatly reduced when the older NRTIs stavudine, zidovudine (AZT) and didanosine were replaced by the 
newer NRTIs tenofovir (TDF) and abacavir (ABC). However, these newer NRTIs may still impair mitochondrial 
function, albeit to a lesser  degree10–13. More recently, mitochondrial dysfunction has also been reported in people 
living with HIV (PLHIV) naive for combined antiretroviral therapy (cART)3,14–16, including in elite-controllers 
17. The factors responsible for cART-independent mtDNA depletion are less well defined and may involve per-
sistent immune  activation18,19. Mitochondrial dysfunction has been suggested to contribute to non-AIDS related 
co-morbidities such as cardiovascular diseases, diabetes, cancer and dementia in  PLHIV20,21.
Platelets are the second most numerous blood cells that are, unlike red blood cells, equipped with mito-
chondria with  mtDNA22,23. Human platelets lack a nucleus and mitochondria are essential in maintaining plate-
let health and lifespan, as recently  reviewed23. MtDNA copy number is considered to reflect mitochondrial 
 function24. Healthy platelets contain between 5 and 8 mitochondria, which serve important processes such as 
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platelet activation, ATP production and platelet  viability25–29. Platelets are traditionally known for their role in 
hemostasis, but an increasing body of evidence supports their role in key processes beyond hemostasis, including 
inflammation and  immunoregulation23. With the importance of mitochondria in platelet metabolism, it is no 
surprise that the health consequences of abnormalities in platelet mitochondrial DNA and function has received 
increased attention, and platelet mtDNA has been proposed to serve as biomarker for different  diseases22,30–32. 
Data on platelet function in PLHIV is contradictory, with some studies reporting increased 33–37, but other 
reduced agonist-induced platelet  reactivity28,38,39.
We hypothesized that mitochondrial dysfunction in PLHIV is associated with reduced platelet mtDNA copies 
and platelet dysfunction. Here, we show that platelet mtDNA copies are lower in PLHIV on long-term cART and 
this was validated in a subgroup of PLHIV using mitochondrial functional assays.
Results
Cohort characteristics. Between December 2016 and February 2017, a total of 208 virally suppressed 
PLHIV on long-term cART and 56 healthy controls (sampled twice) were concurrently enrolled. Baseline char-
acteristics are shown in Table 1. PLHIV were older compared to controls (52 years (IQR: 45.8–59.0) vs 30 years 
(IQR: 25.8–53), respectively, p < 0.001). Median duration of cART use was 6.6 years (IQR: 4.2–11.9).
Platelet mtDNA copies are reduced in PLHIV. Platelet mtDNA copies  (mtDNApl) were signifi-
cantly lower in PLHIV compared to healthy controls (Fig. 1A; median 8.5 copies/platelet (plt) (IQR 7.0–10.7) 
Table 1.  Baseline characteristics. BMI body mass index, cART combination antiretroviral therapy, NRTI 
nucleoside reverse transcriptase inhibitor, NtRTI nucleotide reverse transcriptase inhibitor, NNRTI non-
nucleoside reverse transcriptase inhibitor, PI protease inhibitor, INSTI integrase inhibitor, ABC abacavir, DTG 
dolutegravir, EVG elvitegravir, RAL raltegravir. *Significantly different between cohorts.
PLHIV (n = 208) Healthy controls (n = 56)
Sex (% Female) 17 (8.2) 22 (39.2)*
Age (years, median [IQR]) 52.0 [45.8, 59.0] 30.0 [25.8–53.0]*
BMI (median [IQR]) 24.1 [22.0, 26.0] 23.8 [21.5–25.6]
HIV infection duration (years, median [IQR]) 8.5 [5.0, 14.2]





CD4 nadir (median [IQR]) 250.0 [135.0, 362.5]
CD4 count (median [IQR]) 660.0 [480.0, 812.5]
Undetectable HIV load, n (%) 208 (100)
CD4/CD8 ratio (median [IQR]) 0.8 [0.6, 1.1]
cART duration (years; median [IQR]) 6.6 [4.1, 11.8]
cART regimen
NRTI-use (%) 200 (96.2)
NtRTI-use (%) 97 (46.6)
NNRTI-use (%) 61 (29.3)
PI-use (%) 32 (15.4)
Maraviroc-use (%) 3 (1.4)
INSTI-use (%) 140 (67.3)
ABC (%) 93 (44.7)
DTG (%) 86 (41.3)
EVG (%) 15 (7.2)
RAL (%) 38 (18.3)
Smoking (%) 59 (28.4)
Pack years (median [IQR]) 13.8 [0.0, 28.0]
Hypercholesterolemia (%) 56 (26.9)
Hypertension (%) 40 (19.2)
Diabetes Mellitus (%) 9 (4.3)
No cardiovascular risk factors (%) 50 (24.0)
Statins (%) 56 (26.9)
Aspirin (%) 18 (8.7)
Metformin (%) 9 (4.3)
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vs 12.2 copies/plt (IQR: 9.5–16.6), p < 0.001).  mtDNApl copies correlated inversely with age (Fig. 1B; Pearson’s 
R = − 0.24, p < 0.001).  MtDNApl remained significantly associated with HIV status after correction for age, sex and 
body-mass index (BMI) in a linear regression model (B = 0.77 SE: 0.14, P < 0.0001). When analysis was restricted 
to individuals of 40 years and above (Supplemental Table S1; PLHIV: n = 173 vs HC: n = 22),  mtDNApl remained 
significantly lower in PLHIV compared to controls (Supplemental Fig. S1; PLHIV: 8.4 copies/plt (IQR: 6.6–10.2) 
vs HC: 10.5 copies/plt (IQR: 8.9–14.7), p = 0.001). Similarly, the differences in  mtDNApl between PLHIV and 
controls remained when analysis was restricted to males only (Supplemental Table S2; PLHIV: 8.5 copies/plt 
(IQR: 6.6–10.7) vs HC: 11.6 copies/plt (IQR: 9.3–14.7), p < 0.001).  MtDNApl levels were neither associated with 
duration of cART nor with current CD4 count, CD4 nadir or CD4/CD8 ratio in univariate analysis (Supple-
mental Table S3). Furthermore, no differences in  mtDNApl were found between PI, NNRTI and INSTI-based 
regimens (all p > 0.1; Supplemental Fig. S2).
Although abacavir (ABC)-use has been shown to affect platelet  function40, current ABC use (p = 0.89) or 
cumulative ABC exposure (in days) were not associated with  mtDNApl copies (Supplemental Fig. S2). Conversely, 
PLHIV with prior zidovudine-use (prior AZT-use, n = 46/184; 25%) showed a trend towards lower copies of 
 mtDNApl (AZT-use: 7.8 copies/plt [IQR: 6.0, 9.4] vs never-AZT: 8.6 copies/plt [IQR: 6.9, 10.8], p = 0.055). After 
correcting for age in a linear regression model, a non-significant negative correlation remained (B: − 0.07 (− 0.15 
to 0.01, p = 0.069). Neither cumulative days on AZT (median 2069 days; IQR 792–3180 days; R = − 0.2, p = 0.12), 
nor total NRTI exposure (median 4520 days; IQR: 2734–7955; R = 0.05) correlated with mtDNA-use. Use of 
metformin (p = 0.079) or antihypertensive drugs (p = 0.061) showed a tendency for a lower  mtDNApl copies, 
whereas use of statins (p = 0.74) or acetylsalicylic acid (p = 0.21) did not (Supplemental Fig. S3).
Mitochondrial dysfunction is associated with inflammatory diseases such as atherosclerosis and sepsis in 
HIV-negative  individuals22. Hence, we explored the association of known markers of persisting immune activa-
tion, a known driver of non-AIDS related  comorbidities20,21, with  mtDNApl copy number. Overall, we observed 
higher plasma concentrations of immune activation markers soluble CD14 (sCD14), soluble CD163 (sCD163) 
and high-sensitive CRP (hsCRP) in PLHIV than in controls (Table 2). Among participants older than 40 years, 
only sCD163 remained significantly different between groups (Supplemental Table S1; HIV 741 ng/mL (IQR: 
547–906) vs controls 517 ng/mL (IQR: 443–684), p = 0.01). sCD163 correlated negatively with  mtDNApl copies 
(R = − 0.23, p < 0.001, Fig. 1C), whereas sCD14 (R = − 0.073, p = 0.27) and hsCRP (R: − 0.087, p = 0.2) did not 
(Supplemental Fig. S4).
Platelet mitochondrial dysfunction in PLHIV. Energy demand for platelet ATP production and other 
metabolic processes that are essential for platelet activation is met by the combined actions of glycolysis and 
mitochondrial  OXPHOS41. To validate our findings that the lower platelet mtDNA content is associated with 
platelet mitochondrial dysfunction, and to investigate platelet glycolysis activity, we assessed the metabolic activ-
ity of washed platelets of five PLHIV and five age-sex matched controls to assess membrane potential (Δψm), 
mitochondrial superoxide production  (ROSm) and real-time glycolysis and mitochondrial respiration using the 
Seahorse Extracellular Flux  Analyzer41. Platelet Δψm, as assessed by Tetramethylrhodamine ethyl ester (TMRE) 
fluorescence, was lower in PLHIV compared to controls (1669 ΔMFI (IQR: 911–2233) vs. 4545 ΔMFI (IQR: 
2249–5168) respectively, p = 0.02; Fig. 2E, t-test). In line with reduced Δψm, there was a small increase in  ROSm 
in PLHIV at basal conditions (Fig. 2F; 7654 MFI (IQR: 6777–7798) vs 4956 MFI (IQR: 3840–6284), p = 0.007, 



































































Figure 1.  Platelet mtDNA content. Mitochondrial DNA content in platelets  (mtDNApl) was determined using 
qPCR after normalization for platelet count in isolated platelets. (A) Dotplot showing mtDNA copies per platelet 
in people living with HIV (PLHIV) and controls (HC); the line indicates median and error bars the interquartile 
range (IQR). Student’s t-test was used after inverse rank-based normalization. (B) Normalized (inverse rank 
based)  mtDNApl versus age. (C) Normalized  mtDNApl versus soluble CD163 (a macrophage scavenger receptor). 
Correlations were analyzed using Pearson’s correlation coefficients.
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ity were investigated by assessing the oxygen consumption rate (OCR; measure for mitochondrial respiration/
OXPHOS) and the acidification rate (ECAR; measure for glycolysis). There was a trend towards lower baseline 
platelet mitochondrial respiration (OCR in pmol/min) in PLHIV compared to controls (Fig. 2D; 47.4 pmol/min 
(SD: 11.3) vs 55.1 pmol/min (SD: 12.2), p = 0.084). Additionally, PLHIV had a smaller increase in OCR after 
ex vivo platelet stimulation with both CRP-XL (108% (SD: 16) vs 119% (SD: 16), p = 0.056, Fig. 2B and Supple-
mental Fig. S5) and Thrombin receptor activating peptide (TRAP; 139% (SD: 14) vs 167% (SD: 13), p = 0.037; 
Fig. 2A–C) compared to matched controls.
The fraction of the maximal mitochondrial capacity (maximal OCR after stimulation with the uncoupling 
agent FCCP) used after ex vivo platelet stimulation with TRAP was high in both groups (Supplemental Fig. S6d; 
p > 0.1). This suggests that maximal mitochondrial capacity is a limiting factor in platelet activation. Conversely, 
there was no difference between groups in ECAR (glycolysis) at baseline (Fig. 2B; HIV: 16.0 mpH/min (SD: 3.4) 
vs HC: 14.7 mpH/min (SD: 2.4), p > 0.1) or after ex vivo stimulation. The increase in mitochondrial respiration 
(OCR) after ex vivo stimulation significantly correlated with  mtDNApl (R = 0.77, p = 0.045, n = 7, Fig. 3A) and a 
similar trend was found for basal mitochondrial respiration of platelets (R = 0.61, p = 0.14, n = 7, Fig. 3B). Taken 
together, our data suggest that the lower platelet mtDNA in PLHIV in associated with a concurrent reduction in 
mitochondrial respiration capacity (OXPHOS) without a compensatory increase in glycolysis.
HIV infection is associated with platelet dysfunction. Next, we explored the possible consequences 
of lower  mtDNApl and mitochondrial dysfunction for platelet parameters and function. Platelet counts were 
similar between PLHIV and healthy controls (Table 2), but PLHIV had smaller platelets (mean platelet volume: 
PLHIV:10.1 fL (IQR: 9.7:10.7) vs 10.8 fL (IQR: 10.3–11.3), p < 0.0001), as well as a lower immature platelet frac-
tion (IPF; a marker for freshly released platelets from the bone marrow) compared to controls (Table 2; 3.3% 
(IQR: 2.5–4.6) vs 3.7% (IQR: 2.8–5.9) respectively, p = 0.018). Platelet size (mean platelet volume) correlated 
positively with  mtDNApl (Fig. 5C).
Next, platelet activation and function and function were determined using multiple methods. First, plasma 
markers of in vivo platelet activation (chemokines released from alpha-granules; CCL5, CXCL4, CXCL7) were 
comparable between PLHIV and controls (Table 2). Second, using flow cytometry, the activation status of circu-
lating platelets, as well as their reactivity to ex vivo stimulation by platelet agonists was assessed. In unstimulated 
platelets, the expression of the alpha-granule marker P-selectin (measure of platelet degranulation) and the 
binding of fibrinogen to the activated integrin αIIbβ3 (measure of aggregation; Table 2) were also similar across 
groups. When analysis was restricted to individuals above 40 years of age or male only, unstimulated platelet 
activation was lower in PLHIV compared to controls (Supplemental Tables S1, S2). In line with this observation, 
fibrinogen binding to αIIbβ3 in response to stimulation by adenosine diphosphate (ADP)- and collagen related 
peptide (CRP-XL) was reduced in PLHIV-induced) (Fig. 4A). Differences in P-selectin reactivity across the 
groups were smaller with only a significant difference with a high dose (125 µM) of ADP stimulation showed a 
significant difference between PLHIV and controls (Fig. 4B). We observed no correlations with cART regimens 
containing either NNRTI, PI or INSTI-use as well as ABC and platelet reactivity indices (all P > 0.15). In addition, 
persistent immune activation did not correlate with platelet indices in this cohort (Supplemental Table S4). In 
summary, these data show that platelet reactivity, and especially αIIbβ3 activation is reduced in PLHIV.
Association of  mtDNApl with platelet function. Next, given the role of platelet mitochondria in plate-
let function, we assessed associations of  mtDNApl with platelet reactivity in PLHIV and controls.  MtDNApl cop-
ies did neither correlate with ADP-induced P-selectin expression, nor with binding of fibrinogen to platelets or 
Table 2.  MPV: mean platelet volume. Unstimulated platelet aggregation measured as Fibrinogen binding 
by flowcytometry in median fluorescence intensity (MFI). Unstimulated platelet degranulation measured 
as P-selectin expression by flow cytometry by MFI. Data were analyzed using Mann–Whitney U test. IPF 
immature platelet fraction as a percentage of platelet count (Sysmex, Kobe, Japan); sCD14 serum levels of 
CD14, a marker of monocyte activation; sCD163 serum levels of CD163, a monocyte- and macrophage-specific 
scavenger receptor; hsCRP high sensitive C-reactive protein.
Platelet indices PLHIV (n = 208) Healthy controls (n = 56) p-value
Platelet count  (109/L) 260 [200, 310] 270 [210, 320] 0.126
MPV (fL) 10.1 [9.7, 10.7] 10.8 [10.3, 11.3] < 0.001
IPF (%) 3.3 [2.5, 4.6] 3.7 [2.8, 5.9] 0.018
Unstimulated fibrinogen binding (MFI) 2.0 [1.6, 2.2] 2.1 [1.6, 2.4] 0.072
Unstimulated P-selectin expression (MFI) 2.7 [2.1, 3.2] 2.6 [2.2, 3.0] 0.158
Plasma CCL5 (ng/ml) 2.66 [1.64, 4.29] 2.61 [1.69, 4.18] 0.841
Plasma CXCL4 (ng/mL) 570.0 [290.0, 723.3] 492.9 [306.1, 839.5] 0.201
Plasma CXCL7 (ng/mL) 289.4 [180.3, 465.1] 306.6 [194.2, 609.8] 0.192
sCD14 (ng/mL) 2139.6 [1778.2, 2661.5] 1789.0 [1502.7, 2071.6] < 0.001
sCD163 (ng/mL) 716.5 [528.7, 899.4] 517.3 [410.7, 578.1] < 0.01
hsCRP (ng/mL) 1423.3 [608.8, 2726.3] 651.2 [205.9, 1179.2] < 0.001
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Figure 2.  Platelet energy phenotype determined by the Seahorse extracellular flux analyzer and mitochondrial 
membrane potential and ROS production. Samples were measured with five replicates, 1 ×  107 washed 
platelets per well. Five age-and sex-matched donors per group. (A) Real-time mitochondrial respiration 
depicted as oxygen consumption rate (OCR) at 18 timepoints. Four agonists or inhibitors were added in the 
following order: (1) Thrombin Receptor Activator Peptide-6 (TRAP-6; 50 µM) or medium causing platelet 
activation; (2) Oligomycin which inhibits cellular ATP production; (3) Carbonyl cyanide-4-(trifluoromethoxy) 
phenylhydrazone (FCCP), an uncoupling agent causing maximum oxygen consumption through complex 
IV, and (4) Antimycin A which inhibits all mitochondrial respiration (CRP-XL can be found in Supplemental 
Fig. 9). (B) Energymap showing the change in mitochondrial respiration (as change in OCR) and glycolysis 
(extracellular acidification rate (ECAR) from basal conditions after ex vivo stimulation with platelet agonists. 
((A)) Depicts the real-time ECAR after (1) medium or TRAP-6 (2) oligomycine, (3) FCCP and (4) antimycin 
A. Samples were measured with five replicates, 1 ×  107 washed platelets per well. Five age-and sex-matched 
donors per group. (D) Basal OCR as mean of first three measurements. (E) Membrane potential was determined 
using Tetramethylrhodamine ethyl ester (TMRE) staining with the uncoupler FCCP disrupting mitochondrial 
membrane potential as a negative control for every sample. Data depicted as delta geometric mean fluorescence 
intensity (MFI). (F) Mitochondrial ROS production with MitoSox staining in MFI. Data are depicted as 
mean ± standard error of the mean (SEM) and analyzed using the unpaired student’s T-test.
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mean platelet volume (MPV) in PLHIV (Fig. 5A,B). In controls,  MtDNApl copies were significantly correlated 
with MPV (Fig. 5C) and a positive trend was observed with fibrinogen binding (Fig. 5D).
To further explore the link between platelet reactivity and platelet activation, we performed a principal 
component analysis (PCA) to summarize both platelet activation (plasma markers of platelet activation and 
unstimulated P-selectin expression and fibrinogen binding) and platelet reactivity (P-selectin expression and 
fibrinogen binding after ex vivo ADP and CRP-XL stimulation). This PCA showed that Principal component (PC) 
1 mainly represented platelet reactivity (P-selectin expression and fibrinogen binding after stimulation) whereas 
PC2 mainly represented in vivo platelet activation (plasma markers and unstimulated P-selectin expression 
and fibrinogen binding; Supplemental Fig. S7a,b). We used these derivatives to correlate  mtDNApl with platelet 
reactivity (coordinates on PC1) and platelet activation (coordinates on PC2).  mtDNApl correlated with platelet 
reactivity (Supplemental Fig. S7c; PC1 of platelet parameters vs  mtDNApl, R = 0.14, p = P = 0.024), but not with 
in vivo platelet activation (Supplemental Fig. S7d; PC2 of platelet parameters vs  mtDNApl, R = 0.05, P = 0.41). 
These data suggest that mtDNA depletion is associated with platelet dysfunction with a reduced platelet reactivity 
capacity, but not with increased platelet activation status.
Whereas mitochondrial dysfunction can result in platelet dysfunction, platelet activation itself may also con-
tribute to loss of mitochondria from platelets through the formation of platelet microparticles (PMP)  formation42. 
We therefore studied PMP in a subgroup of 20 PLHIV and age-sex matched controls. No differences in total PMP 
number (Supplemental Fig. S8a), nor PMPs containing mitochondria (Supplemental Fig. S8b) were observed 
across both groups.
Discussion
The present data show that PLHIV on long-term cART have reduced platelet mitochondrial content  (mtDNApl) 
which was associated with platelet mitochondrial dysfunction and reduced energy supply. Platelet mitochondria 
play a key role in platelet metabolism, ATP production and platelet activation and lifespan, and we propose that 
the observed abnormalities in  mtDNApl and platelet mitochondrial function contribute to platelet dysfunction 
in PLHIV.
The literature on platelet function in cART treated individuals is contradictory, with some studies reporting 
increased platelet  reactivity33–37, while others reporting reduced  reactivity28,38,39. This heterogeneity in study 
results may be partly explained by differences in the characteristics of study participants, including the enrol-
ment of PLHIV with detectable plasma HIV-RNA, the degree of persistent immune activation, cART regimens 
and timing of treatment initiation, factors that all have changed considerably over the years. In accordance with 
our present findings, Mesquita et al.28 recently reported decreased platelet reactivity and platelet mitochondrial 
dysfunction in 36 PLHIV on stable cART. In contrast to our findings, platelets in the PLHIV in their cohort 
exhibited increased P-selectin expression. In the present study, not only platelet P-selectin expression, but also 
soluble markers of platelet activation were similar in PLHIV and controls. In addition, PLHIV exhibited a lower 
immature platelet fraction and a similar number of mitochondria-containing platelet microparticles. Together, 
these findings argue against excessive platelet activation being primarily responsible for reduced platelet reactivity 
Figure 3.  Platelet mitochondrial DNA vs mitochondrial respiration measured by Oxygen consumption 
rate (OCR in pmol/min). (A) Correlation plot showing platelet mitochondrial DNA (mtDNA) with change 
in oxygen consumption rate (mitochondrial respiration) measured by Seahorse extracellular flux analyzer 
after ex vivo stimulation with thrombin (TRAP 50 μM). mtDNA was normalized using inverse rank-based 
transformation and Pearson’s correlation coefficient is shown. (B) mtDNA in platelets vs basal OCR in pmol/
min (an average of first three measurements). OCR was measured in triplo and for 5 PLHIV and 2 controls both 
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in PLHIV. Whether mitochondrial depletion contributes to the observed platelet dysfunction in PLHIV remains 
uncertain. A recent study reported that chemotherapy-associated platelet hyporeactivity was caused by mito-
chondrial dysfunction and subsequent reduction in mitochondrial  respiration27. Consistent with these observa-
tions, the lower platelet mtDNA content in PLHIV was associated with a reduction in mitochondrial respiration 
capacity, which may negatively impact platelet reactivity. In our study, however,  mtDNApl levels in PLHIV did 
not correlate with ex vivo platelet reactivity, whereas a positive trend was observed in HIV uninfected controls. 
The fact that all PLHIV exhibited reduced  mtDNApl with little variation in the absolute values may explain the 
absence of a correlation with platelet reactivity measures. Future studies focusing on platelet dysfunction should 
incorporate mitochondrial dysfunction to corroborate our findings.
Age, history of zidovudine (AZT)-use and innate immune activation were all associated with decreased 
 mtDNApl. NRTI-use is a well-known cause of mitochondrial dysfunction and mtDNA  depletion6–8. We found 
that prior AZT-use was a possible risk factor for reduced  mtDNApl, a trend that remained after correcting for 
age and CD4 nadir, whereas total duration of cART-use or duration of HIV infection were not. As platelets are 
short-lived, it is conceivable that mitochondrial mass is reduced during thrombopoiesis and that the known bone 
marrow toxicity of AZT 1 is still present even after switching to newer NRTIs such as TDF or ABC. Even though 
these NRTIs are known to have lower mitochondrial  toxicity1, it is unclear whether long-term treatment does 
not exert any cumulative reduction in  mtDNApl too. While ABC-use has been linked to platelet perturbations 
in multiple  studies43–45, others could not confirm ABC associated platelet  dysfunction35,46. In our study, neither 
 mtDNApl content nor platelet function were associated with current or prior ABC-use. Unfortunately, we could 
not dissect the link between the  mtDNApl, overall NRTI exposure and duration of HIV infection itself, as expo-
sure to NRTIs was high in the total study group. Still, as  mtDNApl content was lower in PLHIV than in controls, 
it is plausible that both NRTIs and HIV itself exert long-term changes in mitochondrial  function2. This possible 
long-term NRTI effect on mitochondrial function in platelets supports recent efforts to implement NRTI sparing 
regimens as viable treatment options for long-term HIV  treatment47. It would be interesting to assess  mtDNApl 
content, as well as platelet function, in PLHIV who are switched to a NRTI sparing regimen.
Figure 4.  Platelet reactivity after collagen (CRP-XL) and ADP stimulation. (A) Platelet fibrinogen binding is 
depicted as mean fluorescence intensity (MFI) after ex vivo stimulation with platelet agonist collagen-related 
peptide (CRP-XL; 33 ng/mL; 625 ng/mL) and adenosine diphosphate (ADP; 1.2 μM, 125 μM). (B) Platelet 
degranulation measured by P-selectin expression is depicted as mean fluorescence intensity (MFI) after ex vivo 
stimulation with CRP-XL (33 ng/mL; 625 ng/mL) and ADP (1.2 μM, 125 μM). Data are shown as dotplot with 
error bars median and interquartile range (IQR). Data were analyzed using unpaired Student’s T-test. People 
living with HIV (PLHIV); healthy controls (HC).
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Mitochondrial dysfunction and depletion have been associated with many diseases such as dementia, neu-
ropsychiatric diseases, and cardiovascular  diseases22,23,30,48. In PLHIV, these (non-AIDS related) co-morbidities 
have also been linked to persistent  inflammation20,21. In our cohort, we indeed found increased levels of hsCRP, 
sCD14 and sCD163, but only the latter parameter was associated with mtDNA levels in platelets. Importantly, 
sCD163 was shown to be independently correlated with overall mortality in PLHIV and the incidence of non-
AIDS related  comorbidities49,50.
Targeting mitochondrial dysfunction and inflammation may help reduce excess mortality and morbidity 
that is associated with HIV infection, even when treated successfully with cART 22,27. Reducing inflammation, 
besides reducing NRTI exposure, could indirectly reduce oxidative stress and mitochondrial dysfunction while 
treatment with ROS scavengers may also have beneficial effects in reducing non-AIDS related co-morbidities.
Multiple methods of mtDNA quantification have been used in whole blood or peripheral blood mononuclear 
cell (PBMC) fractions in HIV and other  diseases14,32. However, different methods of quantification, and hetero-
geneity of the cell composition of whole blood or PBMCs may hamper its  interpretation32,51. It is conceivable 
that platelet mtDNA content could mirror mitochondrial toxicity in other cell types as well. As a single cell-type 
source of mtDNA, platelet mtDNA may indeed serve as a possible biomarker for mitochondrial toxicity and 
non-AIDS related comorbidities associated with mitochondrial dysfunction, such as neurocognitive impairment 
and cardiovascular  disease22.
Our study has limitations associated with its cross-sectional design. Even though sample size was large 
enough to explore the link between inflammation, cART-use,  mtDNApl and platelet function, it lacked power 
to confirm a possible link between  mtDNApl levels and clinical outcomes such as non-AIDS co-morbidities and 
NRTI-related adverse events. Although we observed reduced oxygen consumption in individuals with reduced 
 mtDNApl, the overall reduction of  mtDNApl in PLHIV prevented to investigate functional consequences of 
 mtDNApl depletion in PLHIV. Furthermore, we did not perform immunofluorescence confocal or transmission 
electron microscopy experiments in the current study. In addition, age and sex differed substantially between 
cohorts, with an effect of age on mtDNA content in the uninfected cohort. We explored multiple methods to 
account for these differences using adjusted models and subgroup analyses. The subgroup of above > 40 years 
revealed a significant difference between PLHIV and controls supporting the independent correlation of HIV 
infection in the age-sex adjusted model. Finally, our study included mostly Caucasian men limiting generaliza-
tion of the findings to women and non-Caucasians.
In conclusion, PLHIV under long-term cART have reduced platelet mtDNA content and abnormalities in 
platelet mitochondrial respiration, which may possibly contribute to platelet dysfunction. Given the key role of 
Figure 5.  Association of platelet mitochondrial DNA with platelet reactivity and mean platelet volume (MPV). 
(A, B) correlation of normalized mitochondrial DNA content in platelets  (mtDNApl) and the binding of 
fibrinogen to the activated integrin αIIbβ3 after ex vivo platelet stimulation with ADP (125uM) in PLHIV (A) 
and healthy controls (B). (C, D) correlation of normalized mitochondrial DNA content in platelets  (mtDNApl) 
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platelets and mitochondria in the pathophysiology of long-term complications of HIV, interventions targeting 
platelet mitochondria, such as introducing NRTI sparing regimens, should be considered.
Methods
Patient selection. This cross-sectional, single center, prospective study was performed at the Radboud 
university medical center, a tertiary teaching hospital in The Netherlands. This study is part of the Human Func-
tional Genomics Project (HFGP; www. human funct ional genom icspr oject. org) and was conducted in accordance 
with the Declaration of Helsinki after approval of the ethics committee (CMO Arnhem-Nijmegen, The Neth-
erlands; NL42561.091.12, 2012/550). No animal experiments were performed in the current study. Adult HIV-
1-infected individuals receiving cART for at least six months were included after providing written informed 
consent. Other inclusion criteria were a suppressed viral load (< 200 copies/mL). Exclusion criteria included, use 
of  P2Y12 receptor antagonists (platelet inhibitor), an active hepatitis B or C infection and/or signs of other active 
intercurrent infection other than HIV-1 (e.g. fever in last week or antibiotic-use in last 4 weeks). Healthy con-
trols were concurrently included throughout the duration of inclusion of PLHIV. Exclusion criteria were use of 
medication (excluding oral contraceptives or paracetamol) and/or signs of an active infection in the last month. 
Clinical data was collected by extracting data from electronic medical record (Epic Systems, Verona, WI, USA). 
History of cART use was extracted from the Dutch HIV registry (Stichting HIV-monitoring). In a separate 
validation experiment for mitochondrial function, five virally suppressed male PLHIV (45–60 years) who were 
not using statins or acetylsalicylic acid (ASA), were enrolled together with five age and sex matched controls.
Platelet count and function. Platelet count and parameters were determined using an automated hema-
tology analyzer (Sysmex, Kobe, Japan). Platelet reactivity was determined in citrated whole blood (3.2% sodium 
citrate, Becton Dickinson, Franklin Lakes, NJ, USA) using a flow cytometry based assay as previously described 
between 1 and 3 h after blood  collection52. Platelets were ex vivo stimulated with ADP (1.2 and 125 μM; Sigma-
Aldrich, Zwijndrecht, The Netherlands) and CRP-XL (a kind gift from Prof. Farndale, Cambridge, UK) for 
20 min at room temperature. Platelets were stained using anti-CD61 (Beckman Coulter, Brea. CA, USA), anti-P-
selectin (Biolegend, San Diego, CA, USA) and anti-fibrinogen (DAKO, Santa Clara, CA) antibodies and fixated 
in 0.2% paraformaldehyde. Platelets were identified based on Size (FSC), granularity (SSC) and their expres-
sion of CD61. Degranulation was determined as the membrane expression of α-granule protein P-selectin and 
platelet aggregation was quantified as the amount of fibrinogen binding to the activated integrin αIIbβ3. Platelet 
reactivity was measured on a FC500 flow cytometer (Beckman Coulter, Brea, USA). Data were extracted using 
Kaluza 2.1 (Beckman Coulter), normalized against quality controls to ensure measurement stability and are 
expressed as median fluorescence intensity (MFI). A gating strategy is provided in Supplemental Fig. S1.
Platelet isolation. Platelet rich plasma (PRP) was obtained from citrated plasma (Vacutainer, Beckton-
Dickinson) after centrifugation 156g for 15 min without brake at room temperature (RT). Samples were pro-
cessed within 2  h of blood collection. Platelet count in PRP was measured using an automated hematology 
analyser (Sysmex, Kobe, Japan). Washed platelets were obtained as previously  described53. In short, PRP was 
supplemented with acid citrate dextrose (10%) and prostaglandin  I2 and washed twice with Hepes tyrode’s buffer 
using centrifugation (330g, 20 min).
Platelet microparticles. Peripheral blood was centrifuged at 1000g for 5 min. Plasma was then centrifuged 
at 1500g for 20 min to obtain platelet poor plasma (PPP). 1 mL of PPP was centrifuged for 30 min at 20,000g to 
pellet microparticles (MPs). The MP pellet washed once in 500 µL calcium-free HBS complemented with 0.2% 
bovine serum albumin (pH 7.3) by 45 min centrifugation at 20,000g. MPs were labeled with MitoTracker Deep 
Red (200 nM; Invitrogen, Breda, The Netherlands) in HBS at room temperature containing calcium and subse-
quently stained with anti-CD61, anti-CD62p, Annexin-V (all Biolegend), anti-CD45 and anti-CD41 (both Beck-
man Coulter). MPs were analyzed using a Cytoflex flow cytometer (Beckman Coulter) including the sensitive 
violet Side Scatter (405 nM; VSSC) and FSC for detection of ultrasmall particles (1 µm)54. Platelet MPs (PMPs) 
were selected based on aforementioned markers. Counting beads (Sphero Nano fluorescent, Spherotech, Fulda, 
Germany) of different sizes were included for reference to correct for concentration and size. All solutions for 
PMP isolation and staining were centrifuged at 20,000g for 20 min to remove (fluorescent) aggregates. A gating 
strategy is provided in Supplemental Fig. S2.
mtDNA quantification and mitochondrial function. After platelet count measurement of every PRP 
sample, 500 µL PRP was pelleted by centrifugation (2000g, 10 min at RT without brake) and lysed using Triton-
X100 0.1% for mtDNA quantification.  MtDNApl was measured by real time Quantitative PCR using Mitotox 
Quickscan (Primagen, Amsterdam, Netherlands), Advanced SYBR green Super mix (Bio-rad, Hercules, CA, 
USA) and CFX96 Real time Detection System (Bio-Rad) according to manufacturer’s instructions. The kit 
includes primers and calibrators for quantification. A calibration curve with known mtDNA concentration was 
concurrently measured on every plate to ensure stability and quantification. A dilution curve with PRP showed 
a high correlation coefficient for mtDNA and platelet concentration. mtDNA copies per platelet  (mtDNApl) 
are calculated by dividing mtDNA copy number per well by platelet count in 500 µL of PRP. Contamination of 
leukocyte and erythrocyte was low < 1:10,000. Samples with low platelet counts in PRP (below 50 ×  1012/mL) 
and erythrocyte/leukocyte contamination were excluded (n = 2). Mitochondrial respiration was quantified using 
the 96-well format Seahorse extracellular flux analyzer (Agilent, MA, USA). Washed platelets were plated to 
60,000 platelets/μL and seeded onto Cell-Tak coated XF96 microplates (Corning, Corning, NY, USA). A mito-
chondrial stress test was performed as described  eslewhere41 using oligomycin (1 μM, ATP synthase inhibitor 
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(complex V), reducing mitochondrial respiration), Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone 
(FCCP; 1 μM, uncoupling agent causing maximum mitochondrial respiration), antimycin A (2.5 μM, Com-
plex III inhibitor inhibiting mitochondrial respiration) and 2-deoxy-d-glucose (2DG; 40 mM, inhibits glycoly-
sis) after ex vivo stimulation (all Sigma). Oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR) were determined before and after injection of platelet agonists. Samples were measured in five replicates 
with three measurements after every injection. For mitochondrial respiration measurements using Seahorse 
extracellular flux analyzer, significant outliers were excluded from analysis if measurement was 2× SD below the 
mean value in every timepoint with a maximum of one of the five replicates.
Mitochondrial membrane potential was determined using Tetramethylrhodamine ethyl ester (TMRE, Sigma; 
100 nM at 37 °C for 20 min). A negative control was generated for every sample using FCCP (1 μM at 37 °C for 
10 min). Mitochondrial reactive oxygen species  (ROSm) were detected using the cationic probe MitoSOX Red 
(Invitrogen, Carlsbad, CA, USA (2.5 μM at 37 °C for 30 min). Both probes were quantified in CD61+ cells using 
a Cytoflex flow cytometer (Beckman Coulter).
Plasma markers. Concentrations of three plasma markers of platelet activation: chemokine (C–X–C motif) 
ligand 4 (CXCL4 also known as platelet factor 4), CXCL7 (also known as beta-thromboglobulin) and chemokine 
(C–C motif) ligand (CCL5; also known as RANTES) were determined by ELISA (R and D systems, Minneapolis, 
USA) according to the manufacturer’s instructions in citrated  PPP52. In addition, markers of persistent inflam-
mation, high-sensitive C-reactive protein (hsCRP), sCD163 and sCD14, were measured using ELISA (Quan-
tikine, R and D systems) according to the manufacturer’s instructions in EDTA plasma.
Statistical analyses. Data were analyzed by independent T-test or Mann–Whitney U test. Pearson’s cor-
relations coefficient was used for univariate correlation analyses, unless otherwise stated. An inverse rank-based 
normalization was performed for non-normal data (e.g. mtDNA in platelets). A multivariate linear regression 
model was used to correct for age, body mass index (BMI) and sex. Several sensitivity analyses using subgroups 
(males only and above 40  years) were performed to explore for possible confounding. Principal component 
analysis (PCA) was performed using singular value decomposition to summarize platelet function and correlate 
with  mtDNApl. cART-use was calculated as days on a certain drug, cumulative use of multiple drugs of the same 
class were combined. R studio (CRAN project) and Graphpad Prism version 5.03 were used for analyses.
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